Association of FEF25%-75% and bronchodilator reversibility with asthma control and asthma morbidity in inner-city children with asthma.

PubWeight™: 0.75‹?›

🔗 View Article (PMID 27236218)

Published in Ann Allergy Asthma Immunol on May 26, 2016

Authors

Watcharoot Kanchongkittiphon1, Jonathan M Gaffin2, Lianne Kopel3, Carter R Petty4, Mary E Bollinger5, Rachel L Miller6, Matthew Perzanowski7, Elizabeth C Matsui8, Wanda Phipatanakul9

Author Affiliations

1: Children's Hospital of Michigan, Detroit, Michigan; Department of Pediatrics, Ramathibodi's Hospital, Mahidol University, Bangkok, Thailand.
2: Division of Respiratory Diseases, Boston Children's Hospital, Boston, Massachusetts; Harvard Medical School, Boston, Massachusetts.
3: Division of Respiratory Medicine, Montreal Children's Hospital, Montreal, Quebec, Canada.
4: Clinical Research Center, Boston Children's Hospital, Boston, Massachusetts.
5: Division of Pulmonology and Allergy, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, Maryland.
6: Division of Pulmonary, Allergy, Critical Care Medicine, Columbia University Medical Center, New York, New York; Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York.
7: Department of Environmental Health Sciences, Mailman School of Public Health, Columbia University, New York, New York.
8: Division of Allergy and Immunology, Department of Pediatrics, Johns Hopkins University School of Medicine, Baltimore, Maryland.
9: Harvard Medical School, Boston, Massachusetts; Division of Allergy and Immunology, Boston Children's Hospital, Boston, Massachusetts. Electronic address: wanda.phipatanakul@childrens.harvard.edu.